Fulgent Genetics, Inc. (NASDAQ: FLGT) reported Q3 EPS of ($0.39), $0.07 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $85 million versus the consensus estimate of $64.42 million.

GUIDANCE:

Fulgent Genetics, Inc. sees FY2023 EPS of ~($0.95), versus the consensus of ($0.95). Fulgent Genetics, Inc. sees FY2023 revenue of ~$260 million, versus the consensus of $265.2 million.

For earnings history and earnings-related data on Fulgent Genetics, Inc. (FLGT) click here.